Fibrolamellar carcinoma is a rare and aggressive liver cancer that mostly affects kids and young adults. It makes up about 2% of all liver cancers and has few treatment options.
Scientists have long struggled to use immunotherapy—treatments that help the body’s own immune system fight cancer—against this disease. The new study shows why.
Why the Cancer Hides From the Immune System
Inside the tumor, a thick network of fibrous bands creates a barrier. This barrier stops T‑cells, the soldiers of the immune system, from entering the tumor. The process is called T‑cell exclusion.
Researchers used a method called single‑nucleus transcriptomics to look at each cell’s activity inside the tumor. This gave them a clear picture of the tumor’s micro‑environment and the signals that keep T‑cells out.
A Known Drug Changes the Game
AMD3100 is an FDA‑approved drug that was already used for another condition. In lab tests, AMD3100 broke the barrier and let T‑cells move back into the tumor.
When AMD3100 was combined with an immune‑checkpoint inhibitor, more T‑cells became active and tumor cells died at a higher rate.
What This Means for Patients
The drug is already approved, so it could move faster into clinical trials for fibrolamellar carcinoma. If the results hold up, patients might soon have a new way to make immunotherapy work.
The research team is now looking for liver‑cancer doctors who want to join clinical trials and test this approach in people.